SUMMARY OF INDIRECT COMPARISON TO EVALUATE EFFICACY OF BARICITINIB WITH TARGETED SYNTHETIC AND BIOLOGIC DISEASE ANTI-RHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0

作者：

Emery, Paul ^{[1
]}

Dudler, Jean ^{[2
]}

Smolen, Josef ^{[3
]}

Zerbini, Cristiano ^{[4
]}

Burmester, Gerd ^{[5
]}

Fautrel, Bruno ^{[6
]}

van der Laar, Mart ^{[7
]}

Fleischmann, Roy ^{[8
]}

Fakhouri, Walid ^{[9
]}

De Leonardis, Francesco ^{[10
]}

Zhu, Baojin ^{[11
]}

Kadziola, Zbigniew ^{[12
]}

De La Torre, Inmaculada ^{[13
]}

Perrier, Clementine ^{[14
]}

Taylor, Peter C. ^{[15
]}

机构：

[1] Leeds MSK Biomed Chapel Allerton Hosp, Fac Med & Hlth, Leeds, W Yorkshire, England

[2] HFR Fribourg Hop Cantonal, Dept Rheumatol, Fribourg, Switzerland

[3] Med Univ Vienna, Dept Rheumatol, Vienna, Austria

[4] Ctr Invest Clin, Dept Rheumatol, Sao Paulo, Brazil

[5] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany

[6] Pierre & Marie Curie Univ, Dept Rheumatol, Paris, France

[7] Arthrit Ctr Twente, Dept Rheumatol, Enschede, Netherlands

[8] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA

[9] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA

[10] Eli Lilly & Co, Dept Rheumatol, Indianapolis, IN 46285 USA

[11] Eli Lilly & Co, Real World Analyt Immunol, Indianapolis, IN 46285 USA

[12] Eli Lilly & Co, Real World Analyt Capabil & Data Mart, Indianapolis, IN 46285 USA

[13] Eli Lilly & Co, Dept Med, Indianapolis, IN 46285 USA

[14] Eli Lilly & Co, Dept Med Autoimmune, Indianapolis, IN 46285 USA

[15] Univ Oxford, Botnar Res Ctr, NDORMS, Headington, England

来源：

RHEUMATOLOGY | 2019年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

074

引用

页数：2

共 50 条

[31] RETENTION RATE OF BIOLOGIC AND TARGETED SYNTHETIC ANTI-RHEUMATIC DRUGS IN ELDERLY PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS: DATA FROM ITALIAN GISEA REGISTRY
Manfredi, A.
Iannone, F.
Bugatti, S.
Favalli, E. G.
Franceschini, F.
Atzeni, F.
Bazzani, C.
Cantatore, F. P.
Caporali, R.
Cauli, A.
Conti, F.
Ferraccioli, G.
Foti, R.
Fusaro, E.
Iagnocco, A.
Govoni, M.
Gremese, E.
Lapadula, G.
Rai, A.
Rossini, M.
Semeraro, A.
Sebastiani, M.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 860 - 860
[32] The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs
Pombo-Suarez, Manuel
Gomez-Reino, Juan
PHARMACOLOGICAL RESEARCH, 2019, 148
[33] A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy
Peter K. K. Wong
Hanish Bagga
Claire Barrett
Geoff Chong
Patrick Hanrahan
Teja Kodali
Mona Marabani
H. Miles Prince
John Riordan
Phillip Swarbrick
Ray White
Laurel Young
Current Rheumatology Reports, 2018, 20
[34] A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy
Wong, Peter K. K.
Bagga, Hanish
Barrett, Claire
Chong, Geoff
Hanrahan, Patrick
Kodali, Teja
Marabani, Mona
Prince, H. Miles
Riordan, John
Swarbrick, Phillip
White, Ray
Young, Laurel
CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (10)
[35] SERUM BIOMOLECULES AS POTENTIAL BIOMARKERS OF CLINICAL EFFICACY AND PREDICTORS OF RESPONSE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS PATIENTS
Luque-Tevar, M.
Perez-Sanchez, C.
Pilar, F. U.
Romero-Gomez, M.
Patino-Trives, A. M.
Ruiz, D.
Arias de la Rosa, I.
Abalos-Aguilera, M. D. C.
Ortega Castro, R.
Escudero Contreras, A.
Rodriguez-Escalera, C.
Perez Venegas, J. J.
Ruiz Montesinos, M. D.
Dominguez, C.
Romero Barco, C.
Fernandez-Nebro, A.
Mena-Vazquez, N.
Marenco, J. L.
Uceda, J.
Toledo-Coello, M. D.
Barbarroja Puerto, N.
Aguirre, M. A.
Lopez-Pedrera, C.
Collantes-Estevez, E.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 948 - 948
[36] RHEUMATOID ARTHRITIS PATIENT CLUSTERS WITH FIRST-TIME BIOLOGIC OR TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IDENTIFIED THROUGH DEEP LEARNING
Kalweit, M.
Burden, A. M.
Hugle, T.
Burkard, T.
OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S335 - S335
[37] THE EFFECT OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON WORK PARTICIPATION IN LONGSTANDING RHEUMATOID ARTHRITIS: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW
Alunno, A.
Marques, M. L.
Falzon, L.
Ramiro, S.
Boonen, A.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1309 - 1309
[38] EVALUATION OF ADHERENCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH INFLAMMATORY ARTHRITIS
Lim, Y. C.
Teo, W. G.
Eng, M. N.
Cheen, H. M.
Tay, X. Y.
Yeo, S. I.
Lim, T. G.
ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1800 - 1800
[39] Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study
Joensuu, Jaana T.
Aaltonen, Kalle J.
Aronen, Pasi
Sokka, Tuulikki
Puolakka, Kari
Tuompo, Riitta
Korpela, Markku
Vasala, Mikko
Ilva, Kirsti
Nordstrom, Dan
Blom, Marja
RHEUMATOLOGY, 2016, 55 (10) : 1803 - 1811
[40] The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients
Shahabi, Ahva
Shafrin, Jason
Zhao, Lauren
Green, Sarah
Curtice, Tammy
Marshall, Alexander
Paul, Damemarie
JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 350 - 358

← 1 2 3 4 5 →